WO2024241297 - TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH ERDAFINITIB
National phase entry:
Publication Number
WO/2024/241297
Publication Date
28.11.2024
International Application No.
PCT/IB2024/055103
International Filing Date
24.05.2024
Title **
[English]
TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH ERDAFINITIB
[French]
TRAITEMENT D'UN CARCINOME UROTHÉLIAL LOCALEMENT AVANCÉ OU MÉTASTATIQUE AVEC DE L'ERDAFINITIB
Applicants **
JANSSEN PHARMACEUTICA NV
Inventors
TRIANTOS, Spyridon
DEPRINCE, Kris Emanuel D.
Priority Data
63/504,050
24.05.2023
US
63/590,334
13.10.2023
US
3217575
23.10.2023
CA
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6122 | |
| EPO | Filing, Examination, Granting | 82555 | |
| Japan | Filing, Examination, Granting | 4436 | |
| South Korea | Filing, Examination, Granting | 6766 | |
| USA | Filing, Examination, Granting | 38340 |
Total:
138,219
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the treatment of locally advanced or metastatic urothelial carcinoma (mUC) with erdafitinib in patients with FGFR altered mUC who progressed on or after 1 or more prior treatments that included a checkpoint inhibitor, in particular an anti-PD-(L)1 agent.[French]
La présente invention concerne le traitement d'un carcinome urothélial métastatique (mUC) ou localement avancé avec de l'erdafitinib chez des patients atteints de mUC modifié par FGFR qui progresse lors d'un ou de plusieurs traitements antérieurs ou après ceux-ci faisant appel à un inhibiteur de point de contrôle, en particulier un agent anti-PD-(L)1.